PROMIS NEUROSCIENCES INC. Net Income (Loss) Available to Common Stockholders, Basic
PROMIS NEUROSCIENCES INC. (PMN) reported Net Income (Loss) Available to Common Stockholders, Basic of -$11.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-13
- PROMIS NEUROSCIENCES INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$11.73M.
- PROMIS NEUROSCIENCES INC. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$8.24M.
- PROMIS NEUROSCIENCES INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$10.67M.
- PROMIS NEUROSCIENCES INC. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$11.58M, a 224.84% decline year-over-year.
- PROMIS NEUROSCIENCES INC. net income (loss) available to common stockholders, basic for fiscal 2025 was -$39.72M, a 1529.33% decline from fiscal 2024.
- PROMIS NEUROSCIENCES INC. net income (loss) available to common stockholders, basic for fiscal 2024 was $2.78M.
- PROMIS NEUROSCIENCES INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$13.21M, a 173.15% decline from fiscal 2022.
- PROMIS NEUROSCIENCES INC. net income (loss) available to common stockholders, basic for fiscal 2022 was $18.06M, a 84.50% increase from fiscal 2021.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$11.73M 10-Q · filed 2026-08-13 | -$19.97M 10-Q · filed 2026-08-13 | -$30.65M derived: sum of 3 quarters · filed 2026-08-13 | -$42.23M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | -$8.24M 10-Q · filed 2026-05-12 | -$18.92M derived: sum of 2 quarters · filed 2026-05-12 | -$30.50M derived: sum of 3 quarters · filed 2026-05-12 | -$40.62M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | -$10.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$22.25M derived: sum of 2 quarters · filed 2026-03-25 | -$32.37M derived: sum of 3 quarters · filed 2026-08-13 | -$39.72M 10-K · filed 2026-03-25 | |||
| 2025-09-30 | -$11.58M 10-Q · filed 2025-11-12 | -$21.70M derived: sum of 2 quarters · filed 2026-08-13 | -$29.05M 10-Q · filed 2025-11-12 | -$29.28M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-06-30 | -$10.12M 10-Q · filed 2026-08-13 | -$17.46M 10-Q · filed 2026-08-13 | -$17.70M derived: sum of 3 quarters · filed 2026-08-13 | -$8.43M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | -$7.35M 10-Q · filed 2026-05-12 | -$7.59M derived: sum of 2 quarters · filed 2026-05-12 | $1.69M derived: sum of 3 quarters · filed 2026-05-12 | -$933.94K derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | -$238.21K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $9.04M derived: sum of 2 quarters · filed 2026-03-25 | $6.41M derived: sum of 3 quarters · filed 2026-03-25 | $2.78M 10-K · filed 2026-03-25 | |||
| 2024-09-30 | $9.28M 10-Q · filed 2025-11-12 | $6.65M derived: sum of 2 quarters · filed 2025-11-12 | $3.02M 10-Q · filed 2025-11-12 | -$563.35K derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | -$2.62M 10-Q · filed 2025-08-13 | -$6.26M 10-Q · filed 2025-08-13 | -$9.84M derived: sum of 3 quarters · filed 2025-08-13 | -$12.20M derived: sum of 4 quarters · filed 2025-08-13 | |||
| 2024-03-31 | -$3.64M 10-Q · filed 2025-05-12 | -$7.22M derived: sum of 2 quarters · filed 2025-05-12 | -$9.58M derived: sum of 3 quarters · filed 2025-05-12 | -$11.89M derived: sum of 4 quarters · filed 2025-05-12 | |||
| 2023-12-31 | -$3.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$5.94M derived: sum of 2 quarters · filed 2025-03-31 | -$8.25M derived: sum of 3 quarters · filed 2025-03-31 | -$13.21M 10-K · filed 2025-03-31 | $13.21M 10-K · filed 2024-04-01 | ||
| 2023-09-30 | -$2.36M 10-Q · filed 2024-11-14 | -$4.67M derived: sum of 2 quarters · filed 2024-11-14 | -$9.63M 10-Q · filed 2024-11-14 | $19.23M derived: sum of 4 quarters · filed 2024-11-14 | |||
| 2023-06-30 | -$2.31M 10-Q · filed 2024-08-08 | -$7.27M 10-Q · filed 2024-08-08 | $21.59M derived: sum of 3 quarters · filed 2024-08-08 | $15.63M derived: sum of 4 quarters · filed 2024-08-08 | |||
| 2023-03-31 | -$4.96M 10-Q · filed 2024-05-14 | $23.90M derived: sum of 2 quarters · filed 2024-05-14 | $17.94M derived: sum of 3 quarters · filed 2024-05-14 | $15.20M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $28.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $22.90M derived: sum of 2 quarters · filed 2024-04-01 | $20.16M derived: sum of 3 quarters · filed 2024-04-01 | $18.06M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$5.96M 10-Q · filed 2023-11-14 | -$8.70M derived: sum of 2 quarters · filed 2023-11-14 | -$10.80M 10-Q · filed 2023-11-14 | $10.88M 10-Q · filed 2022-11-14 | -$8.65M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | -$2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$4.84M 10-Q · filed 2023-08-14 | $4.79M 10-Q · filed 2022-08-12 | -$2.70M derived: sum of 3 quarters · filed 2023-08-14 | -$1.53M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | -$2.09M 10-Q · filed 2023-05-15 | $47.21K derived: sum of 2 quarters · filed 2023-05-15 | $1.22M derived: sum of 3 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $3.31M derived: sum of 2 quarters · filed 2023-03-08 | $9.79M 10-K · filed 2023-03-08 | ||||
| 2021-09-30 | $1.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $7.65M 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | $6.48M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |